Drugs.com - Clinical Trials

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not...

Feb 9, 2025 - 21:44
 0
Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia
Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not...
Read More

Tags:

Previous Article

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treat...

Next Article

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to ...

Related Posts

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025  0

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Announce Positive Ziftome...

Feb 9, 2025  0

GRIN Therapeutics Receives FDA Orphan Drug Designation for Radiprodil for the Treatment of GRIN-Related Neurodevelopmental Disorder

GRIN Therapeutics Receives FDA Orphan Drug Designation ...

Mar 19, 2025  0